COVID-19 Information

Publications

Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer.
Axelrod ML, Nixon MJ, Gonzalez-Ericsson PI, Bergman RE, Pilkinton MA, McDonnell WJ, Sanchez V, Opalenik S, Loi S, Zhou J, Mackay S, Rexer BN, Abramson VG, Jansen VM, Mallal SA, Donaldson J, Tolaney SM, Krop I, Garrido-Castro AC, Marotti JD, Shee K, Miller TW, Sanders M, Mayer IA, Salgado R, Balko JM
Clin Cancer Res. 2020 Aug 21; pii: clincanres.3685.2019. doi: 10.1158/1078-0432.CCR-19-3685. Epub 2020 Aug 21.
PMID: 32826327

Identification of let-7f-5p as a novel biomarker of recurrence in non-muscle invasive bladder cancer.
Shee K, Seigne JD, Karagas MR, Marsit CJ, Hinds JW, Schned AR, Pettus JR, Armstrong DA, Miller TW, Andrew AS
Cancer Biomark. 2020 Jun 28; doi: 10.3233/CBM-191322. Epub 2020 Jun 28.
PMID: 32623385

Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board.
Bernhardt EB, Chamberlin MD, Gorlov IP, de Abreu FB, Bloch KJ, Peterson JD, Tsongalis GJ, Shirai K, Dragnev KH, Miller TW, Tafe LJ
Pract Lab Med. 2020 Aug;21:e00174. doi: 10.1016/j.plabm.2020.e00174. Epub 2020 Jun 12.
PMID: 32613070

Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
Chamberlin MD, Wells JD, Shee K, Bean JR, Marotti JD, Wells WA, Trask HW, Kolling FW, Bhatt A, Kaufman PA, Schwartz GN, Gemery JM, McNulty NJ, Tsapakos MJ, Barth RJ, Arrick BA, Gui J, Miller TW
Breast Cancer Res Treat. 2020 Aug;182(3):665-677. doi: 10.1007/s10549-020-05714-2. Epub 2020 Jun 19.
PMID: 32562118

AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer Cells.
Hampsch RA, Wells JD, Traphagen NA, McCleery CF, Fields JL, Shee K, Dillon LM, Pooler DB, Lewis LD, Demidenko E, Huang YH, Marotti JD, Goen AE, Kinlaw WB, Miller TW
Clin Cancer Res. 2020 Jul 15;26(14):3707-3719. doi: 10.1158/1078-0432.CCR-20-0269. Epub 2020 Apr 22.
PMID: 32321715

Endocytosis of very low-density lipoproteins: an unexpected mechanism for lipid acquisition by breast cancer cells.
Lupien LE, Bloch K, Dehairs J, Traphagen NA, Feng WW, Davis WL, Dennis T, Swinnen JV, Wells WA, Smits NC, Kuemmerle NB, Miller TW, Kinlaw WB
J Lipid Res. 2020 Feb;61(2):205-218. doi: 10.1194/jlr.RA119000327. Epub 2019 Dec 5.
PMID: 31806729

Statistical determination of synergy based on Bliss definition of drugs independence.
Demidenko E, Miller TW
PLoS One. 2019;14(11):e0224137. doi: 10.1371/journal.pone.0224137. Epub 2019 Nov 25.
PMID: 31765385

Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy.
Shee K, Wells JD, Jiang A, Miller TW
PLoS One. 2019;14(11):e0224267. doi: 10.1371/journal.pone.0224267. Epub 2019 Nov 4.
PMID: 31682620

A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition.
Shee K, Wells JD, Ung M, Hampsch RA, Traphagen NA, Yang W, Liu SC, Zeldenrust MA, Wang L, Kalari KR, Yu J, Boughey JC, Demidenko E, Kettenbach AN, Cheng C, Goetz MP, Miller TW
Clin Cancer Res. 2020 Jan 1;26(1):159-170. doi: 10.1158/1078-0432.CCR-18-2213. Epub 2019 Sep 26.
PMID: 31558472

Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
Miller TW, Traphagen NA, Li J, Lewis LD, Lopes B, Asthagiri A, Loomba J, De Jong J, Schiff D, Patel SH, Purow BW, Fadul CE
J Neurooncol. 2019 Sep;144(3):563-572. doi: 10.1007/s11060-019-03258-0. Epub 2019 Aug 9.
PMID: 31399936

Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer.
Hosford SR, Shee K, Wells JD, Traphagen NA, Fields JL, Hampsch RA, Kettenbach AN, Demidenko E, Miller TW
Mol Oncol. 2019 Aug;13(8):1778-1794. doi: 10.1002/1878-0261.12528. Epub 2019 Jul 9.
PMID: 31180176

Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
Chen Y, Wang Y, Salas LA, Miller TW, Mark K, Marotti JD, Kettenbach AN, Cheng C, Christensen BC
Breast Cancer Res. 2019 Jan 25;21(1):14. doi: 10.1186/s13058-018-1090-z. Epub 2019 Jan 25.
PMID: 30683142

Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.
Shee K, Muller KE, Marotti J, Miller TW, Wells WA, Tsongalis GJ
Am J Pathol. 2019 May;189(5):956-965. doi: 10.1016/j.ajpath.2018.08.020. Epub 2018 Oct 29.
PMID: 30385093

Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER+ breast cancer.
Shee K, Jiang A, Varn FS, Liu S, Traphagen NA, Owens P, Ma CX, Hoog J, Cheng C, Golub TR, Straussman R, Miller TW
FASEB J. 2019 Feb;33(2):1644-1657. doi: 10.1096/fj.201801241R. Epub 2018 Aug 30.
PMID: 30161001

Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer.
Yang W, Schwartz GN, Marotti JD, Chen V, Traphagen NA, Gui J, Miller TW
Oncotarget. 2018 Feb 6;9(10):8810-8822. doi: 10.18632/oncotarget.24256. Epub 2018 Jan 15.
PMID: 29507656

Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.
Floros KV, Lochmann TL, Hu B, Monterrubio C, Hughes MT, Wells JD, Morales CB, Ghotra MS, Costa C, Souers AJ, Boikos SA, Leverson JD, Tan M, Serra V, Koblinski JE, Arribas J, Prat A, Pare L, Miller TW, Dozmorov MG, Harada H, Windle BE, Scaltriti M, Faber AC
Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2594-E2603. doi: 10.1073/pnas.1717820115. Epub 2018 Feb 23.
PMID: 29476008

Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer.
Shee K, Yang W, Hinds JW, Hampsch RA, Varn FS, Traphagen NA, Patel K, Cheng C, Jenkins NP, Kettenbach AN, Demidenko E, Owens P, Faber AC, Golub TR, Straussman R, Miller TW
J Exp Med. 2018 Mar 5;215(3):895-910. doi: 10.1084/jem.20171818. Epub 2018 Feb 7.
PMID: 29436393

Trailblazing Precision Oncology for Rare Tumor Subtypes.
Shee K, Miller TW
Oncologist. 2018 Feb;23(2):143-144. doi: 10.1634/theoncologist.2017-0494. Epub 2017 Nov 20.
PMID: 29158369

Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer.
Yang W, Hosford SR, Traphagen NA, Shee K, Demidenko E, Liu S, Miller TW
FASEB J. 2018 Mar;32(3):1222-1235. doi: 10.1096/fj.201700477R. Epub 2018 Jan 3.
PMID: 29127189

P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site.
Marotti JD, Muller KE, Tafe LJ, Demidenko E, Miller TW
Int J Breast Cancer. 2017;2017:4537532. doi: 10.1155/2017/4537532. Epub 2017 Jun 15.
PMID: 28698809

Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.
Hampsch RA, Shee K, Bates D, Lewis LD, Desire L, Leblond B, Demidenko E, Stefan K, Huang YH, Miller TW
Oncotarget. 2017 Mar 28;8(13):21806-21817. doi: 10.18632/oncotarget.15586.
PMID: 28423521

Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin.
Shee K, Kono AT, D'Anna SP, Seltzer MA, Lu X, Miller TW, Chamberlin MD
Case Rep Oncol. 2016 Sep-Dec;9(3):840-846. doi: 10.1159/000453608. Epub 2016 Dec 8.
PMID: 28101033

Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer.
Hosford SR, Dillon LM, Bouley SJ, Rosati R, Yang W, Chen VS, Demidenko E, Morra RP Jr, Miller TW
Clin Cancer Res. 2017 Jun 1;23(11):2795-2805. doi: 10.1158/1078-0432.CCR-15-2764. Epub 2016 Nov 30.
PMID: 27903677

The PREX1/Rac signaling axis: Potential as a biomarker and therapeutic target in breast cancer.
Dillon LM, Miller TW
Mol Cell Oncol. 2015 Jul-Sep;2(3):e996016. doi: 10.1080/23723556.2014.996016. Epub 2015 Apr 30.
PMID: 27308485

Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.
Chamberlin MD, Bernhardt EB, Miller TW
J Cell Biochem. 2016 Nov;117(11):2454-63. doi: 10.1002/jcb.25590. Epub 2016 Jun 3.
PMID: 27146558

Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
Muller KE, Marotti JD, de Abreu FB, Peterson JD, Miller TW, Chamberlin MD, Tsongalis GJ, Tafe LJ
Exp Mol Pathol. 2016 Jun;100(3):421-5. doi: 10.1016/j.yexmp.2016.04.002. Epub 2016 Apr 16.
PMID: 27095739

Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
Yang W, Hosford SR, Dillon LM, Shee K, Liu SC, Bean JR, Salphati L, Pang J, Zhang X, Nannini MA, Demidenko E, Bates D, Lewis LD, Marotti JD, Eastman AR, Miller TW
Clin Cancer Res. 2016 May 1;22(9):2250-60. doi: 10.1158/1078-0432.CCR-15-2276. Epub 2016 Jan 5.
PMID: 26733612

Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
Tafe LJ, Gorlov IP, de Abreu FB, Lefferts JA, Liu X, Pettus JR, Marotti JD, Bloch KJ, Memoli VA, Suriawinata AA, Dragnev KH, Fadul CE, Schwartz GN, Morgan CR, Holderness BM, Peterson JD, Tsongalis GJ, Miller TW, Chamberlin MD
Oncologist. 2015 Sep;20(9):1011-8. doi: 10.1634/theoncologist.2015-0097. Epub 2015 Jul 23.
PMID: 26205736

The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Bean JR, Hosford SR, Symonds LK, Owens P, Dillon LM, Yang W, Shee K, Schwartz GN, Marotti JD, Muller KE, Rosenkranz KM, Barth RJ, Chen VS, Agarwal VR, Miller TW
Breast Cancer Res Treat. 2015 Jan;149(1):69-79. doi: 10.1007/s10549-014-3201-6. Epub 2014 Dec 10.
PMID: 25491778

Estrogen receptor alpha and androgen receptor are commonly expressed in well-differentiated liposarcoma.
Ingram DR, Dillon LM, Lev DC, Lazar A, Demicco EG, Eisenberg BL, Miller TW
BMC Clin Pathol. 2014;14:42. doi: 10.1186/1472-6890-14-42. Epub 2014 Oct 22.
PMID: 25349530

P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.
Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW
Oncogene. 2015 Jul 23;34(30):3968-76. doi: 10.1038/onc.2014.328. Epub 2014 Oct 6.
PMID: 25284585

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.
Hosford SR, Miller TW
Pharmgenomics Pers Med. 2014;7:203-15. doi: 10.2147/PGPM.S52762. Epub 2014 Aug 6.
PMID: 25206307

Therapeutic targeting of cancers with loss of PTEN function.
Dillon LM, Miller TW
Curr Drug Targets. 2014 Jan;15(1):65-79.
PMID: 24387334

Managing breast cancers with low estrogen receptor and HER2 by drugging both.
Miller TW
Clin Cancer Res. 2014 Feb 1;20(3):528-30. doi: 10.1158/1078-0432.CCR-13-2994. Epub 2013 Dec 18.
PMID: 24352641

Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.
Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, Gomez H, Cook RS, Arteaga CL
Cancer Res. 2013 Oct 15;73(20):6346-58. doi: 10.1158/0008-5472.CAN-13-1385. Epub 2013 Aug 21.
PMID: 23966295

Endocrine resistance: what do we know?
Miller TW
Am Soc Clin Oncol Educ Book. 2013; doi: 10.1200/EdBook_AM.2013.33.e37.
PMID: 23714450

Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.
Fox EM, Arteaga CL, Miller TW
Front Oncol. 2012;2:145. doi: 10.3389/fonc.2012.00145. Epub 2012 Oct 16.
PMID: 23087906

Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.
Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL
Mol Cancer Ther. 2012 Oct;11(10):2301-5. doi: 10.1158/1535-7163.MCT-12-0511. Epub 2012 Aug 9.
PMID: 22879364

Membrane-initiated estrogen signaling: oncogenic or impotent?
Miller TW
Expert Rev Endocrinol Metab. 2012 Jul;7(4):411-413. doi: 10.1586/eem.12.26.
PMID: 30754162

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, Gonzalez-Angulo AM, Mills GB, Pinto JA, Gomez HL, Arteaga CL
Nat Med. 2012 Jul;18(7):1052-9. doi: 10.1038/nm.2795.
PMID: 22683778

Initiating breast cancer by PIK3CA mutation.
Miller TW
Breast Cancer Res. 2012 Feb 7;14(1):301. Epub 2012 Feb 7.
PMID: 22315990

The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium.
Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, Sanchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS
Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):221-6. doi: 10.1073/pnas.1115802109. Epub 2011 Dec 16.
PMID: 22178756

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.
Miller TW, Rexer BN, Garrett JT, Arteaga CL
Breast Cancer Res. 2011;13(6):224. doi: 10.1186/bcr3039. Epub 2011 Nov 1.
PMID: 22114931

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.
Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, Gonzalez-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL
Cancer Discov. 2011 Sep;1(4):338-51. doi: 10.1158/2159-8290.CD-11-0101. Epub 2011 Jul 20.
PMID: 22049316

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.
Miller TW, Balko JM, Arteaga CL
J Clin Oncol. 2011 Nov 20;29(33):4452-61. doi: 10.1200/JCO.2010.34.4879. Epub 2011 Oct 17.
PMID: 22010023

A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
Fox EM, Miller TW, Balko JM, Kuba MG, Sanchez V, Smith RA, Liu S, Gonzalez-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CL
Cancer Res. 2011 Nov 1;71(21):6773-84. doi: 10.1158/0008-5472.CAN-11-1295. Epub 2011 Sep 9.
PMID: 21908557

A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Gonzalez-Angulo AM, Mills GB, Miller WR, Wu H, Shyr Y, Arteaga CL
Clin Cancer Res. 2011 Apr 1;17(7):2024-34. doi: 10.1158/1078-0432.CCR-10-2567. Epub 2011 Feb 23.
PMID: 21346144

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.
Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, Garcia-Echeverria C, Shyr Y, Arteaga CL
J Clin Invest. 2010 Jul;120(7):2406-13. doi: 10.1172/JCI41680. Epub 2010 Jun 7.
PMID: 20530877

Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.
Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, de Matos Granja N, Narasanna A, Cook RS, Kennedy JP, Lindsley CW, Arteaga CL
Clin Cancer Res. 2009 Dec 1;15(23):7266-76. doi: 10.1158/1078-0432.CCR-09-1665. Epub 2009 Nov 24.
PMID: 19934303

Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, Nolting DD, Buck JR, Zhao P, Ansari MS, Baldwin RM, Gore JC, Schiff R, Arteaga CL, Manning HC
Clin Cancer Res. 2009 Jul 15;15(14):4712-21. doi: 10.1158/1078-0432.CCR-08-2635. Epub 2009 Jul 7.
PMID: 19584166

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.
Miller TW, Perez-Torres M, Narasanna A, Guix M, Stal O, Perez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP, Lindsley CW, Arteaga CL
Cancer Res. 2009 May 15;69(10):4192-201. doi: 10.1158/0008-5472.CAN-09-0042. Epub 2009 May 12.
PMID: 19435893

Aromatase is phosphorylated in situ at serine-118.
Miller TW, Shin I, Kagawa N, Evans DB, Waterman MR, Arteaga CL
J Steroid Biochem Mol Biol. 2008 Nov;112(1-3):95-101. doi: 10.1016/j.jsbmb.2008.09.001. Epub 2008 Sep 4.
PMID: 18822378

Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.
Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL, Messer A
Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11563-8. Epub 2005 Aug 1.
PMID: 16061794

Intrabody applications in neurological disorders: progress and future prospects.
Miller TW, Messer A
Mol Ther. 2005 Sep;12(3):394-401.
PMID: 15964243

A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease.
Miller TW, Zhou C, Gines S, MacDonald ME, Mazarakis ND, Bates GP, Huston JS, Messer A
Neurobiol Dis. 2005 Jun-Jul;19(1-2):47-56.
PMID: 15837560

DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype.
Miller TW, Shirley TL, Wolfgang WJ, Kang X, Messer A
Mol Ther. 2003 May;7(5 Pt 1):572-9.
PMID: 12718899